DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
LAPACHONE
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma; Neoplasms
Unknown
LAPACHONE
×
Maximum Phase:
2
First Approval:
None
UNII:
6N4FA2QQ6A
Molecule Type:
Small molecule
Molecular Formula:
C15H14O3
Molecular Weight:
242.27
AlogP:
2.75
PSA:
43.37
HBD:
0.0
HBA:
#RotB:
0.0
Source:
CTS-1027
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C; Hepatitis C, Chronic
Unknown
CTS-1027
×
Maximum Phase:
2
First Approval:
None
UNII:
2QD3F58224
Molecule Type:
Small molecule
Molecular Formula:
C19H20ClNO6S
Molecular Weight:
425.89
AlogP:
3.21
PSA:
101.93
HBD:
2.0
HBA:
#RotB:
6.0
Source:
REVAPRAZAN
2
Small molecule
Investigational
Unknown
Unknown
Gastroesophageal Reflux
Unknown
REVAPRAZAN
×
Maximum Phase:
2
First Approval:
None
UNII:
5P184180P5
Molecule Type:
Small molecule
Molecular Formula:
C22H23FN4
Molecular Weight:
362.45
AlogP:
5.1
PSA:
41.05
HBD:
1.0
HBA:
#RotB:
3.0
Source:
MIVAVOTINIB CITRATE
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Ovarian Neoplasms; Lymphoma, Large B-Cell, Diffuse
Tyrosine-protein kinase SYK inhibitor
MIVAVOTINIB CITRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
6ZJ8V3Q0H1
Molecule Type:
Small molecule
Molecular Formula:
C23H29FN6O8
Molecular Weight:
536.52
AlogP:
1.55
PSA:
97.86
HBD:
3.0
HBA:
#RotB:
3.0
Source:
TESETAXEL
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Melanoma; Prostatic Neoplasms, Castration-Resistant; Stomach Neoplasms; Breast Neoplasms
Unknown
TESETAXEL
×
Maximum Phase:
2
First Approval:
None
UNII:
UG97LO5M8Y
Molecule Type:
Small molecule
Molecular Formula:
C46H60FN3O13
Molecular Weight:
881.99
AlogP:
4.56
PSA:
201.51
HBD:
3.0
HBA:
#RotB:
10.0
Source:
HP184
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
HP184
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FIALURIDINE
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis B, Chronic; Herpes Simplex
Unknown
FIALURIDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
53T7IN77LC
Molecule Type:
Small molecule
Molecular Formula:
C9H10FIN2O5
Molecular Weight:
372.09
AlogP:
-1.27
PSA:
104.55
HBD:
3.0
HBA:
#RotB:
2.0
Source:
HQP1351
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
HQP1351
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TETRAHYDROPALMATINE
2
Small molecule
Investigational
Unknown
Unknown
Cocaine-Related Disorders
Unknown
TETRAHYDROPALMATINE
×
Maximum Phase:
2
First Approval:
None
UNII:
3X69CO5I79
Molecule Type:
Small molecule
Molecular Formula:
C21H25NO4
Molecular Weight:
355.43
AlogP:
3.38
PSA:
40.16
HBD:
0.0
HBA:
#RotB:
4.0
Source:
MARALIXIBAT CHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Cholangitis, Sclerosing; Liver Cirrhosis, Biliary; Alagille Syndrome; Pruritus
Ileal bile acid transporter inhibitor
MARALIXIBAT CHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
V78M04F0XC
Molecule Type:
Small molecule
Molecular Formula:
C40H56ClN3O4S
Molecular Weight:
710.42
AlogP:
6.62
PSA:
70.08
HBD:
1.0
HBA:
#RotB:
13.0
Source:
HYDROXYPROGESTERONE
2
Small molecule
Investigational
Unknown
Unknown
Premature Birth
Unknown
HYDROXYPROGESTERONE
×
Maximum Phase:
2
First Approval:
None
UNII:
21807M87J2
Molecule Type:
Small molecule
Molecular Formula:
C21H30O3
Molecular Weight:
330.47
AlogP:
3.84
PSA:
54.37
HBD:
1.0
HBA:
#RotB:
1.0
Source:
APILIMOD
2
Small molecule
Investigational
Unknown
Unknown
Common Variable Immunodeficiency; Crohn Disease; Severe Acute Respiratory Syndrome
1-phosphatidylinositol 3-phosphate 5-kinase inhibitor
APILIMOD
×
Maximum Phase:
2
First Approval:
None
UNII:
GFW2K84S4L
Molecule Type:
Small molecule
Molecular Formula:
C23H26N6O2
Molecular Weight:
418.5
AlogP:
3.08
PSA:
84.76
HBD:
1.0
HBA:
#RotB:
8.0
Source:
GW468816
2
Small molecule
Investigational
Unknown
Unknown
Tobacco Use Disorder
Glutamate [NMDA] receptor antagonist
GW468816
×
Maximum Phase:
2
First Approval:
None
UNII:
3WGI8FOO62
Molecule Type:
Small molecule
Molecular Formula:
C20H17ClN2O3
Molecular Weight:
368.82
AlogP:
3.8
PSA:
69.64
HBD:
2.0
HBA:
#RotB:
2.0
Source:
AZD1446
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Attention Deficit Disorder with Hyperactivity
Neuronal acetylcholine receptor; alpha4/beta2 agonist
AZD1446
×
Maximum Phase:
2
First Approval:
None
UNII:
ANR9OP1V17
Molecule Type:
Small molecule
Molecular Formula:
C11H13ClN2O2
Molecular Weight:
240.69
AlogP:
1.22
PSA:
45.48
HBD:
1.0
HBA:
#RotB:
1.0
Source:
EX-527
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
EX-527
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C13H15ClN2O
Molecular Weight:
250.73
AlogP:
2.5
PSA:
55.12
HBD:
2.0
HBA:
#RotB:
1.0
Source:
INCB-047986
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Hodgkin Disease; Myelodysplastic Syndromes; Arthritis, Rheumatoid
Tyrosine-protein kinase JAK1 inhibitor
INCB-047986
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EPELSIBAN BESYLATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
EPELSIBAN BESYLATE
×
Maximum Phase:
2
First Approval:
None
UNII:
H629P9T4UN
Molecule Type:
Small molecule
Molecular Formula:
C36H44N4O7S
Molecular Weight:
676.84
AlogP:
2.76
PSA:
91.84
HBD:
1.0
HBA:
#RotB:
6.0
Source:
EGANELISIB
2
Small molecule
Investigational
Unknown
Unknown
Unknown
PI3-kinase p110-gamma subunit inhibitor
EGANELISIB
×
Maximum Phase:
2
First Approval:
None
UNII:
FOF5155FMZ
Molecule Type:
Small molecule
Molecular Formula:
C30H24N8O2
Molecular Weight:
528.58
AlogP:
3.24
PSA:
125.13
HBD:
2.0
HBA:
#RotB:
4.0
Source:
ZENOCUTUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms
ErbB-2/ErbB-3 heterodimer inhibitor
ZENOCUTUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
AE72RB1W1X
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SR-123781A
2
Unknown
Investigational
Unknown
Unknown
Coronary Artery Disease; Venous Thromboembolism
Unknown
SR-123781A
×
Maximum Phase:
2
First Approval:
None
UNII:
V952P6826M
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AGS-16C3F
2
Unknown
Investigational
Unknown
Unknown
Carcinoma, Renal Cell
Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 binding agent
AGS-16C3F
×
Maximum Phase:
2
First Approval:
None
UNII:
VC1D38AGN9
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MM-111
2
Unknown
Investigational
Unknown
Unknown
Breast Neoplasms
ErbB-2/ErbB-3 heterodimer inhibitor
MM-111
×
Maximum Phase:
2
First Approval:
None
UNII:
6IJ4CQY76O
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BASIMGLURANT
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder; Depressive Disorder, Major; Fragile X Syndrome
Metabotropic glutamate receptor 5 modulator
BASIMGLURANT
×
Maximum Phase:
2
First Approval:
None
UNII:
3110E3AO8S
Molecule Type:
Small molecule
Molecular Formula:
C18H13ClFN3
Molecular Weight:
325.77
AlogP:
4.08
PSA:
30.71
HBD:
0.0
HBA:
#RotB:
1.0
Source:
RITANSERIN
2
Small molecule
Investigational
Unknown
Unknown
Cocaine-Related Disorders
Unknown
RITANSERIN
×
Maximum Phase:
2
First Approval:
None
UNII:
145TFV465S
Molecule Type:
Small molecule
Molecular Formula:
C27H25F2N3OS
Molecular Weight:
477.58
AlogP:
5.48
PSA:
37.61
HBD:
0.0
HBA:
#RotB:
5.0
Source:
ORM-12741
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease
Unknown
ORM-12741
×
Maximum Phase:
2
First Approval:
None
UNII:
D26C95A960
Molecule Type:
Small molecule
Molecular Formula:
C18H23NO2
Molecular Weight:
285.39
AlogP:
3.78
PSA:
25.61
HBD:
0.0
HBA:
#RotB:
2.0
Source:
CHF6001
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
CHF6001
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TD-139
2
Small molecule
Investigational
Unknown
Unknown
Idiopathic Pulmonary Fibrosis; Severe Acute Respiratory Syndrome
Galectin-3 inhibitor
TD-139
×
Maximum Phase:
2
First Approval:
None
UNII:
60Y0GUO72B
Molecule Type:
Small molecule
Molecular Formula:
C28H30F2N6O8S
Molecular Weight:
648.65
AlogP:
-0.12
PSA:
201.26
HBD:
6.0
HBA:
#RotB:
8.0
Source:
TESNATILIMAB
2
Antibody
Investigational
Unknown
Unknown
Alopecia Areata; Crohn Disease
Unknown
TESNATILIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
2B860WP9F0
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ROMYELOCEL-L
2
Cell
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute
Unknown
ROMYELOCEL-L
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Cell
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VIXARELIMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Oncostatin-M-specific receptor subunit beta inhibitor
VIXARELIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
W25GO3A75W
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ETAVOPIVAT
2
Small molecule
Investigational
Unknown
Unknown
Anemia, Sickle Cell
Unknown
ETAVOPIVAT
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C22H23N3O6S
Molecular Weight:
457.51
AlogP:
0.77
PSA:
109.27
HBD:
1.0
HBA:
#RotB:
5.0
Source:
TEGOBUVIR
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C; Hepatitis C, Chronic
Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor
TEGOBUVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
5NOK5X389M
Molecule Type:
Small molecule
Molecular Formula:
C25H14F7N5
Molecular Weight:
517.41
AlogP:
6.73
PSA:
56.49
HBD:
0.0
HBA:
#RotB:
4.0
Source:
CENERSEN
2
Oligonucleotide
Investigational
Unknown
Unknown
Myelodysplastic Syndromes; Leukemia, Myeloid, Acute
p53 mRNA antisense inhibitor
CENERSEN
×
Maximum Phase:
2
First Approval:
None
UNII:
K6KJ8AZ05F
Molecule Type:
Oligonucleotide
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CALCITONIN EEL
2
Protein
Investigational
Unknown
Unknown
Hemiplegia
Unknown
CALCITONIN EEL
×
Maximum Phase:
2
First Approval:
None
UNII:
R5527T0R0U
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
(+)-SECOISOLARICIRESINOL
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms
Unknown
(+)-SECOISOLARICIRESINOL
×
Maximum Phase:
2
First Approval:
None
UNII:
M8QRJ7JEJH
Molecule Type:
Small molecule
Molecular Formula:
C20H26O6
Molecular Weight:
362.42
AlogP:
2.12
PSA:
99.38
HBD:
4.0
HBA:
#RotB:
9.0
Source:
1
2
…
126
127
128
129
130
131
132
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA